Dr Sarah Calaghan, Associate Professor of Cardiac Physiology at the Faculty of Biological Sciences at Leeds said: 'The idea that exercise makes
statin side effects worse might be a misconception - what really matters is the intensity of exercise.
For several decades, cholesterol-lowering
statin medications have been at the forefront of cardiovascular disease management, as a large body of research supports their benefits in reducing the risk of heart attack and stroke.
Dr Sarah Calaghan, associate professor in cardiac physiology from the University of Leeds said: "The idea that exercise makes
statin side effects worse might be a misconception - what really matters is the intensity of exercise.
Scientists say their findings suggest why only some people experience muscle pain after taking
statins. Dr Sarah Calaghan, associate professor in cardiac physiology from the University of Leeds, said: "The idea that exercise makes
statin side effects worse might be a misconception.
FICTION:
Statins increase your risk of developing dementia Often described as one of the greatest health challenges of our time, dementia is a cause for concern for many
statin users.
FICTION:
Statins increase your risk of developing dementia Often described as one of the greatest health challenges of our heart disease in on
statins time, dementia is a cause for concern for many
statin users.
Keywords:
Statin, Alternate-day regimen, Muscle disorders, Tendon disorders, Adverse effects.
TUESDAY, July 2, 2019 (HealthDay News) -- There may be a dose-dependent relationship between
statin therapy and new-onset diabetes across the duration of
statin use, according to a study recently published in Diabetes Metabolism Research and Reviews.
"A number of studies have found that when people start taking
statins, they're less likely to participate in other health activities, such as exercise, believing the
statin is protecting them," says Dr Kendrick.
After an extensive review of the literature pertaining to
statin safety and tolerability the researchers reported the compiled findings from several randomized controlled trials, in addition to observational data, where required.
Moderate-intensity
statin I therapy (with pravastatin or simvastatin) doesn't prevent progression to dementia in patients at increased risk.
Matching was based on the following criteria: subject's general practitioner (GP) practice, age (within one year of the HZ patient), sex, and lack of prior
statin exposure.